AGAP3 and Cryptococcal meningitis: Survival with this strategy was dramatically improved, with a 30-month survival of 71% for those who received fluconazole and later developed cryptococcal meningitis while the 2-month survival was 0% in those CrAg positive patients who developed cryptococcal meningitis and had not received fluconazole [13].